The report provides an overview of the situation of pharmacies in Spain in the year 2024, based on data from IQVIA Sell-Out on a sample of 7,000 pharmacies, extrapolated to a universe of 22,311 pharmacy offices.
The average value of each purchase was 30 euros, and the acquired units were 2.4 products per visit to the pharmacy. The average revenue for each pharmacy in the year 2024 amounted to 1,124,372 euros, representing a 6 percent growth compared to 2023. Out of this revenue, 790,099 euros corresponded to medications (a 6% increase from 2023) and 334,273 euros to ‘consumer health’, with a 5 percent increase from the previous year. Additionally, 75 percent of the medications purchased were branded, while 25 percent were generics.
The report also categorizes pharmacies into three groups based on their revenue. The first group consists of 4,462 pharmacies (20%) that generated 2,178,407 million euros; the second group includes 6,693 pharmacies (30%) with a revenue of 1,235,839, and the third group comprises 11,156 pharmacies (50%) with a revenue of 635,921 euros.
«The snapshot of pharmacies in 2024 shows a dynamic sector with moderate growth, but with increasingly marked differences between pharmacies. The traditional structure based on capillarity and healthcare service remains, but commercial pressure and the varying growth rates of categories like ‘consumer health’ accentuate inequalities. This situation calls for a serious reflection on the need to continue protecting the Spanish pharmacy model, which historically has ensured equitable and universal access to medication,» said the editor of the Observatory, Enrique Granda.
MARCH DATA
The Observatory highlights that the data on public consumption of medications in March 2025 indicate an increase in the funded market compared to 2024. Annually, the funded market experiences a growth of 614.9 million euros, a higher amount than the previous month, attributed to Easter falling in March last year.
The year-on-year accumulated growth is 5.02 percent. The demand for funded medications, i.e., the number of prescriptions billed on a year-on-year basis, increased by 37.7 million prescriptions compared to the previous year, exceeding 1.1 billion prescriptions (1,161). The total market increased by +10.3% in value and +4.2% in volume (number of units) in the month of March.
